definiens: means the diagnosis, prevention and treatment of infections caused by : 5 ( i ) the pathogens listed in the WHO R&D blueprint priority ( December 2015 or January 2017 ) as updated from time to time ( including : Arenaviral hemorrhagic fevers ( including Lassa Fever ), Crimean Congo Haemorrhagic Fever ( CCHF ), Filoviral diseases ( including Ebola and Marburg ), Middle East Respiratory Syndrome Coronavirus ( MERS -CoV ) ( or ot her highly pathogenic coronaviral diseases, such as SARS ), Nipah and related henipaviral diseases, Rift Valley Fever ( RVF ), Severe Fever with Thrombocytopenia Syndrome ( SFTS ) and Zika unless, at the time of CEPI ’s request to work with Partner, Partner is a lready committed to working with Gates based on a proposal according to the Global Access Commitments Agreement dated February 13, 2015 ; ( ii ) Chikungunya ; ( iii ) Lassa Fever ; and ( iv ) novel or previously unrecognized pathogens likely to result in an Outbreak or risk of an Outbreak unless, at the time of CEPI ’s request to work with Partner, Partner is already committed to working with Gates based on a proposal according to the Global Access Commitments Agreement dated February 13, 2015 or unless products to treat such infections are already commercialized, commercialization has failed, or Partner has a commercial interest in such products . Such commercial interest of Partner is assumed for the following pathogens : [ * * * * * ] . If CEPI is intere sted to develop a product with respect to such novel or previously unrecognized pathogen under this Agreement, it shall notify Partner hereof and Partner shall respond within [ * * * * * ] business days as of the notification whether the product is within or out side the Field, and with respect to any such pathogen other than the ones listed above for which the commercial interest is assumed, Partner shall provide information on its commercial interest . With respect to pathogens which fall under this ( iv ), for whi ch the Partner has previously declared commercial interest, and for which the commercial interest is not assumed, CEPI may after six ( 6 ) months as from Partner ’s providing the aforementioned information reasonably request from Partner a confirmation includ ing appropriate information, that Partner ’s commercial interest continues and consequently such pathogen remains to be outside the Field